- Current use of prohibited medication(s) or requirement for prohibited medication(s) during study treatment NOTE: Current use of anticoagulants is permitted if the subject meets the PTT and INR entry criteria (see Table 6) and monitored in accordance with local institutional practice. NOTE: Subjects who are currently on an aspirin regimen or using aspirin containing product(s) at the time of screening MUST agree to discontinue aspirin or aspirin-containing product(s) at least 10 days prior to first dose of study treatment. After study Day 22 and completion of all assessments to be performed during this period, including tumor biopsies, the aspirin regimen or use of aspirin-containing product(s) may be resumed CRPC cohort only: subjects may remain on LHRH agonists (i.e., leuprolide, goserelin, triptorelin or histrelin), low dose prednisone or prednisolone (up to 10 mg/day), or bisphosphonates (if on stable dose for at least four weeks) without interruption and remain eligible for this study.